More than 12,000 Chinese blood plasma products recalled in HIV scare
Thousands of blood plasma products sold by a Chinese state-owned pharmaceutical company have been found to be contaminated with HIV.
- The treatment was produced by China’s second-largest blood product manufacturer
- The source of the contamination is believed to be a donation from an HIV-positive donor
- No-one has been found to be infected by HIV, according to local media
More than 12,000 units of plasma have been recalled after products in the same batch tested positive for the virus, according to state-owned media The Beijing News.
The batch of intravenous immunoglobulin was produced by Shanghai Xinxing Pharmaceutical Co. Ltd., the country’s second-largest blood product manufacturer.
Immunoglobulins, also known as antibodies, are produced by plasma cells to fight pathogens in the body.
Intravenous immunoglobulin therapy is often used to treat immune disorders caused by illnesses such as leukaemia, or acute inflammation and chemotherapy infections.
The presence of the HIV virus in the product was first detected by the Jiangxi Provincial Centre for Disease Control and Prevention, in southeast China, according to state media.
The Beijing News said the Chinese National Health Commission (NHC) had advised hospitals across the country to stop using the contaminated batch and monitor all patients who have been administered the treatment.
The reports said 12,226 bottles of the product had been distributed to a dozen hospitals in different provinces.
So far no-one has been found to be infected with HIV due to the treatment, said a representative of the Jianxi Province Disease Control Centre, who said the “chance of an infection from an injection of the product is minimal”.
The source of the contamination is suspected to be from an HIV-positive blood donation.
The case is the latest medical scandal originating from China.
In July last year, the Chinese Food and Drug Administration found vaccine manufacturer Changseng Biotechnology had violated standards in the production of a rabies vaccine.